12.03.24 -- How To Overcome Immune Rejection In iPSC-based Gene Therapy

Are you up to the task of bringing a biologic drug to market? Do you have a strategy and plan for moving forward? Here, we explore this from a biopharma process development and manufacturing perspective.

A pharma company sought a CMO partner with commercial manufacturing capabilities and expertise as well as exemplary quality systems to find a cost-effective process to produce the API for a new drug.

This study evaluates a cost-effective alternative to Proleukin for expanding T cells that demonstrates comparable performance across cell viability, subpopulation ratios, and clinical consistency.

Dr. John Lewis, Founder and CEO, Entos Pharmaceuticals, presents RNA Vaccine Development to Phase I.

Physiologically based pharmacokinetic (PBPK) modeling advancements are helping drug sponsors mitigate risk in preclinical and clinical studies through early identification of poor absorption properties.

Lonza principle scientist Deanna Mudie Ph.D. covers the design of dissolution media to support biopredictive dissolution testing and how the properties of a drug and formulation affect performance.

Consider the PentaMice platform, a collection of five wildtype mouse strains bred for increased MHC class II diversity — and how we're leveraging it for COVID-19 antibody discovery.

Leveraging computer-aided synthesis design technology and route scouting in the early stages of development can aid you in designing an efficient and cost-effective path to API manufacturing.

This organ-on-a-chip model minimizes drug absorption while maintaining the essential architecture. Explore the specifications of this product engineered to model the human liver.